Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Consensus Price Target from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $51.90.

TWST has been the topic of a number of research analyst reports. Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Barclays dropped their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Robert W. Baird lifted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Scotiabank lifted their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 1,057 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the completion of the sale, the senior vice president now directly owns 121,013 shares in the company, valued at approximately $5,029,300.28. The trade was a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 659 shares of the company’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the completion of the sale, the insider now owns 94,481 shares of the company’s stock, valued at approximately $3,926,630.36. The trade was a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 83,754 shares of company stock valued at $3,869,144 in the last three months. 3.92% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

Several large investors have recently added to or reduced their stakes in TWST. State Street Corp grew its holdings in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the period. Geode Capital Management LLC grew its holdings in shares of Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after purchasing an additional 26,145 shares during the period. Thrivent Financial for Lutherans purchased a new position in shares of Twist Bioscience during the 3rd quarter worth $43,992,000. Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Finally, Fred Alger Management LLC grew its holdings in shares of Twist Bioscience by 17.1% during the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock worth $34,660,000 after purchasing an additional 112,272 shares during the period.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $43.60 on Wednesday. Twist Bioscience has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -12.11 and a beta of 1.85. The stock’s 50-day simple moving average is $46.40 and its 200-day simple moving average is $46.41.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.